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Although HIV/AIDS has been anything but neglected over the last decade, opportunistic infec-
tions (OIs) are increasingly overlooked as large-scale donors shift their focus from acute care
to prevention and earlier antiretroviral treatment (ART) initiation. Of these OIs, cryptococcal
meningitis, a deadly invasive fungal infection, continues to affect hundreds of thousands of
HIV patients with advanced disease each year and is responsible for an estimated 15%–20% of
all AIDS-related deaths [1, 2]. Yet cryptococcal meningitis ranks amongst the most poorly
funded “neglected” diseases in the world, receiving 0.2% of available relevant research and
development (R&D) funding, according to Policy Cures’ 2016 Global Funding of Innovation
for Neglected Diseases (G-Finder) Report [3, 4].
Although cryptococcal meningitis is not formally recognised by the World Health Organi-
sation (WHO) or PLOS Neglected Tropical Diseases (PLOS NTDs) as a neglected tropical dis-
ease (NTD), it is listed in the G-Finder Neglected Diseases report, as it disproportionately
affects people in low- and middle-income countries (LMICs), with market failure evident for
existing essential antifungal medicines and an urgent need for new, effective, and less toxic
medicines. PLOS NTDs defines NTDs as a “group of poverty-promoting chronic infectious dis-
eases, which primarily occur in rural areas and poor urban areas of LMICs” [5] and according
to the WHO, NTDs are “a proxy for poverty and disadvantage”, have “an important impact on
morbidity and mortality”, and are relatively “neglected by research” [6]. Although the greatest
burden of cryptococcal disease is undoubtedly related to HIV, we demonstrate herein that
cryptococcal meningitis meets both the WHO and PLOS NTDs definitions of an NTD, as the
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disease (1) disproportionately affects populations in poverty and causes substantial morbidity
and mortality, (2) primarily affects populations living in tropical and subtropical areas, (3) is
immediately amenable to broad control, elimination, or eradication, and (4) is neglected by
research [7].
Morbidity, mortality, and poverty associated with cryptococcal
meningitis
As the most common cause of meningoencephalitis in sub-Saharan Africa and Southeast Asia,
cryptococcal meningitis disproportionately affects populations in some of the most economi-
cally disadvantaged regions of the world [1–3]. Mortality rates remain high, ranging between
20% and 60% with treatment and up to 100% without, affecting the most economically produc-
tive age groups [1, 8–11]. Significant morbidity is often encountered, with severe headaches
occurring weeks to months before presentation and potential long-term sequelae including
blindness and deafness [12–14]. Such morbidity and mortality places a substantial economic
burden on patients and their families, resulting in lost productivity and wages as well as patient-
transportation and medical costs. Effective treatments are intensive, expensive (for example,
where available, first-line induction therapy with amphotericin B therapy costing over US$200
in Uganda), and available only in hospitals (due to the need for intravenous [IV] administration
of amphotericin B and need for close laboratory monitoring for toxicities) [15, 16].
A disease of the tropics and subtropics
ART scale-up is ultimately the key to reducing cryptococcal meningitis mortality, as has been
demonstrated in Europe and North America [17, 18]. However, the burden of morbidity and
mortality in LMICs has remained largely unchanged and shows no sign of abating [2, 19–22].
The number of severely immunosuppressed patients not yet accessing ART has remained rela-
tively constant and, in some instances, even increased [23–28]. Data from a recent meta-analy-
sis estimated that over half of patients in Africa had progressed to AIDS with CD4 counts
<200 cells/mm3 by the time they initiated ART [29], despite over a decade of ART program
implementation and scale-up.
While new WHO guidance on a strategy of universal HIV testing and treatment has the
potential to prevent cryptococcal disease, poor retention in care and ART failure currently
have a significant impact on the incidence of cryptococcal meningitis in Africa. In many hospi-
tals, over half of cryptococcal meningitis cases now occur in patients previously prescribed
ART, either in the early months following initiation of ART as unmasking of subclinical infec-
tion or, more commonly, later, as a consequence of nonadherence and/or ART failure [28, 30].
There is no sign of a reduction in the high mortality rates for HIV-associated cryptococcal
meningitis, driven by late presentation, delayed diagnosis, and inadequate access to and effi-
cacy of current antifungal medicines [31]. Though a number of HIV programs in South and
Southeast Asia have achieved some success in terms of ART retention and early detection, the
proportion of patients presenting to care with blood samples testing positive for cryptococcal
antigen (CrAg) rival those seen in many settings in Africa, demonstrating that cryptococcal
meningitis still presents a significant problem, even if absolute numbers of cases are lower
[32–35].
Lack of R&D
A common misconception is that funding for cryptococcal meningitis comes under the
umbrella of HIV. In reality, cryptococcal meningitis has fallen into a research and policy gap
[4]. The research gap is most evident in drug development, as only 3 antifungal medicines—
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amphotericin B, flucytosine (5-FC), and fluconazole—are currently used for the treatment of
cryptococcal meningitis, all of which are decades old [21, 31]. Current WHO guidelines rec-
ommend 2 weeks of amphotericin B and 5-FC as the initial intensive induction phase, followed
by a step-down to fluconazole for the consolidation and maintenance phases of treatment [36,
37]. However, this gold standard induction phase remains aspirational for most LMICs. Both
amphotericin B and 5-FC are unavailable in the majority of LMICs, and the cheaper, more
widely available fluconazole is an inadequate treatment for induction therapy [10]. In addition
to patchy drug registration, amphotericin B is often not administered due to issues with toxic-
ity (i.e., anaemia and renal impairment), poor laboratory monitoring facilities, cost barriers,
and requirements for cold-chain shipment/storage at 4˚C [31, 38]. Although there are 3 strin-
gent regulatory authority (SRA)-approved generic manufacturers of 5-FC (Meda Pharm
[recently acquired by Mylan], Sigmapharm, Valeant), none are currently registered in Africa
[31, 38, 39, 40] despite compelling data for 5-FC’s use in combination with either amphotericin
B or fluconazole during the induction phase of treatment (regimens both recommended in the
latest WHO guidelines [8, 14, 36, 37, 40]). Instead, fluconazole is widely available, well toler-
ated, and used for all phases of cryptococcal treatment despite clear evidence that fluconazole
alone is a poorly effective medicine when used during the intensive induction phase, with
10-week mortality consistently >50% [8, 9, 10, 41].
R&D into the manufacture of new or improved therapies is currently inadequate. In 2015,
R&D for cryptococcal meningitis totalled US$5.8 million (just over 1% of the R&D budget
afforded to tuberculosis [US$567 million]), placing it in the bottom tier of neglected diseases,
receiving support essentially from 3 public health funders: United States National Institutes of
Health (NIH), United Kingdom Medical Research Council (MRC), and Australian National
Health and Medical Research Council [3]. Funding for HIV/AIDS does not currently encom-
pass OIs such as cryptococcal meningitis and, as yet, neither has it fallen under the umbrella of
NTD funding. Very few new drugs for cryptococcal meningitis are in the human safety and
dose-finding trial stage of development. VT-1129 and VT-1598 (Viamet Pharmaceuticals) are
long-acting, azole-like compounds developed with assistance from the NIH’s Therapeutics for
Rare and Neglected Diseases programme. In vitro and animal models have demonstrated
excellent activity and good oral pharmacokinetics, safety profile, and central nervous system
penetration (www.viamet.com/pipeline.asp [42]). In addition, T-2307, which targets the fungal
mitochondrial membrane, has completed initial human safety and dose-finding trials in the
US (www.toyama-chemical.co.jp/en/rd/pipeline/index.html [43]). Oral formulations of
amphotericin B (Matinas Biopharma) and compounds with activity against Cryptococcus neo-
formans (including AN 2690 [Anacor Pharmaceuticals], ASP 2397 [VICAL], and Ar 12 [Arno
Therapeutics]) are currently only in preclinical stages of development. No additional new anti-
fungal medicines have been developed for the treatment of cryptococcal meningitis in over 2
decades.
Strategies for control of cryptococcal meningitis
Despite the challenges, 2 strategies for the control and treatment of cryptococcal meningitis
exist that together could make a significant impact: screen-and-treat programs for CrAg and
delivery of short-course improved therapies [6]. CrAg screening of severely immunosup-
pressed patients (typically with CD4 counts100 cells/mm3), which is recommended by the
WHO and the President’s Emergency Plan for AIDS Relief (PEPFAR), combined with pre-
emptive antifungal treatment can prevent or detect at an early stage a significant proportion of
cryptococcal meningitis cases, as the antigen can be detected in blood for weeks to months
prior to the development of clinical disease. There are sensitive and specific CrAg lateral flow
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005575 June 29, 2017 3 / 7
assays (CrAg LFAs) that can be used for diagnosis either in the laboratory or at the point of
care. The strategy is highly cost-effective and has recently shown a mortality benefit when
combined with increased adherence support and early detection of tuberculosis (TB) [16, 44].
Although CrAg screening has been adopted into policy by over 20 countries, few have commit-
ted resources to implementing such programs; attention brought to cryptococcal meningitis as
an NTD could help move such policy to action and begin saving lives.
With regard to treatment, optimized, sustainable regimens using existing antifungal medi-
cines, drug development, and testing of repurposed drugs could significantly reduce the case
fatality rate. Simplified treatment regimens consisting of short-course combination amphoteri-
cin B therapy and a purely oral combination of fluconazole and flucytosine are currently being
tested in African LMICs with results expected in 2017 (ACTA trial, ISRCTN45035509). Lipo-
somal formulations of amphotericin B offer a far better-tolerated alternative to traditional for-
mulations. The AMBITION-cm trial is comparing the efficacy of 1 high dose of liposomal
amphotericin in combination with fluconazole for HIV-associated cryptococcal meningitis
(AMBITION-cm, ISRCTN10248064). A few intermittent doses could prove cost-effective if
hospital admission duration was reduced, and there is precedent for efforts to increase access.
In September 2016, Gilead extended a donation program to the WHO to make an additional
380,000 vials of liposomal amphotericin available at cost to continue treating patients with vis-
ceral leishmaniasis over 5 years [45]. If Gilead’s program were expanded to cover cryptococcal
meningitis, this could make improved, simplified treatment of meningitis far more accessible
to resource-limited populations where disease burden is highest.
Repurposing of established drugs has also been applied to the search for new medicines
[46]. This approach may expedite translation into clinical practice and reduce drug-develop-
ment costs. Sertraline and tamoxifen are 2 such drugs that are fungicidal against C. neofor-
mans, with good central nervous system penetration and synergy with fluconazole [30]. Both
drugs are being studied separately as new adjunctive therapies for HIV-associated meningitis.
Lastly, raised intracranial pressure affects approximately one third of patients, and manag-
ing this common, debilitating, life-threatening complication improves patient outcomes [47,
48]. However, access to manometers, used to measure intracranial pressure, remains inade-
quate in LMICs and needs to be addressed alongside validation of simple measures to deter-
mine flow rates of cerebrospinal fluid (CSF) through spinal needles [49].
Consideration for inclusion in NTD list
Whilst debate continues as to whether cryptococcal meningitis should be listed as an NTD,
affected persons in LMICs remain neglected, with opportunities missed to both prevent dis-
ease and provide effective treatment to reduce mortality. Stating that increased ART coverage
alone will obviate the problem of HIV-associated cryptococcal meningitis in LMICs is not ten-
able; the evidence, with striking data from Botswana of ongoing cryptococcal meningitis cases
despite excellent ART coverage, shows that this has not been the case to date [22]. Patients
with advanced HIV-related cryptococcal meningitis will continue to present to hospitals in
LMICs for the foreseeable future.
In 2013, the Cryptococcal Meningitis Action Group (CryptoMAG) was formed to improve
access to diagnostic tests and essential antifungal medicines and to disseminate clinical best
practices for treatment and prevention in LMICs. The debate over whether or not cryptococcal
disease is an NTD detracts from cryptococcal meningitis being both HIV related and also
urgently needing the interventions (funding, policy drives, and drug pipelines) from which
NTDs benefit. We therefore call on the global health community, PLOS NTDs, UNITAID, The
Global Fund, and WHO to declare cryptococcal meningitis an NTD and press for urgent
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funding and policy drives to target optimisation and rollout of CrAg-screening programs,
access to 5-FC and liposomal amphotericin B, and new drug development.
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